Chimerix names new CEO

Chimerix (CMRX) has named its chief medical officer, Michelle Berrey, as CEO to replace Kenneth Moch, who has resigned to "pursue other interests."

Berrey will continue to serve as Chimerix's CMO.

In March, Chimerix caused a storm by initially refusing to supply its Brincidofovir (CMX001) treatment to a seven-year-old boy who was dying from an adenovirus infection.

The company explained that Brincidofovir wasn't authorized, but it eventually caved and provided the drug. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs